Quantcast
Channel: Recent PR Buzz (prbuzz.com) Press Releases by Category:
Viewing all 3121 articles
Browse latest View live

Recent Study: Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2013

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye). Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556408_keratoconjunctivitis_sicca_dry_eye_pipeline.aspx?afid=101
------------------------------------------------------------

Scope

* A snapshot of the global therapeutic scenario for Keratoconjunctivitis sicca (Dry Eye).
* A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Keratoconjunctivitis sicca (Dry Eye) Overview
Therapeutics Development
An Overview of Pipeline Products for Keratoconjunctivitis sicca (Dry Eye)
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Development by Companies
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Products under Development by Companies
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Keratoconjunctivitis sicca (Dry Eye) Therapeutics Development
Alcon, Inc.
Seikagaku Corporation
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Lux Biosciences, Inc.
Sylentis
Novagali Pharma SA
Isotechnika Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Rigel Pharmaceuticals, Inc.
Bayer AG
InSite Vision Incorporated
iCo Therapeutics Inc.
Can-Fite BioPharma Ltd.
NovaBay Pharmaceuticals, Inc.
Circadian Technologies Limited
RegeneRx Biopharmaceuticals, Inc.
Hanall Pharmaceutical Co., Ltd.
R-Tech Ueno, Ltd.
Digna Biotech, S.L.
SCYNEXIS, Inc.
Parion Sciences, Inc.
SARcode Corporation
PharmaNova Inc.
Resolvyx Pharmaceuticals, Inc
Morria Biopharmaceuticals Plc
ESBATech AG
SIFI Pharma
Lee's Pharmaceutical Holdings Limited
Altacor Ltd.
Mimetogen Pharmaceuticals Inc.
Eleven Biotherapeutics
Advancell
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
diquafosol tetrasodium - Drug Profile
R-348 - Drug Profile
secukinumab - Drug Profile
P-17 - Drug Profile
disitertide - Drug Profile
Xerophthalmia Program - Drug Profile
voclosporin - Drug Profile
CF-101 - Drug Profile
RGN-259 - Drug Profile
rebamipide - Drug Profile
lifitegrast - Drug Profile
Cyclokat - Drug Profile
Cyclokat - Drug Profile
cyclosporine - Drug Profile
RX-10001 - Drug Profile
ProtoCure Eye Drops - Drug Profile
bertilimumab - Drug Profile
mapracorat - Drug Profile
ESBA-105 - Drug Profile
RX-20001 - Drug Profile
RU-101 - Drug Profile
SF-102 - Drug Profile
rivoglitazone - Drug Profile
dexamethasone acetate - Drug Profile
ALT-088 - Drug Profile
VGX-100 - Drug Profile
HL-036 - Drug Profile
DA-6034 - Drug Profile
difluprednate - Drug Profile
Autologous Serum Eyedrops - Drug Profile
ozagrel - Drug Profile
MIM-D3 - Drug Profile
SYL-1001 - Drug Profile
bromfenac sodium - Drug Profile
LX-214 - Drug Profile
OPRX - Drug Profile
SCY-641 - Drug Profile
LX-212 - Drug Profile
HO/05/09 - Drug Profile
SI-614 - Drug Profile
NOP-4 - Drug Profile
NOP-5 - Drug Profile
EBI-005 - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556408&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.



Smallpox - Pipeline Review, H1 2013 - New Study Released

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Smallpox - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smallpox, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smallpox. Smallpox - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556438_smallpox_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Smallpox.
* A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Smallpox pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Smallpox.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smallpox Overview
Therapeutics Development
An Overview of Pipeline Products for Smallpox
Smallpox Therapeutics under Development by Companies
Smallpox Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Smallpox Therapeutics - Products under Development by Companies
Smallpox Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Smallpox Therapeutics Development
Inovio Biomedical Corporation
Bavarian Nordic A/S
Symphogen A/S
Nanotherapeutics, Inc.
Aphios Corporation
CEL-SCI Corporation
CytoGenix, Inc.
SIGA Technologies, Inc.
TapImmune Inc.
MacroGenics, Inc.
AlphaVax, Inc.
EpiVax, Inc.
Chimerix, Inc.
NanoBio Corporation
DynPort Vaccine Company LLC
Smallpox - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CMX001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sym-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cidofovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imvamune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imvamune - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNA Vaccine For Viral Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNA Vaccine For Smallpox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smallpox Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smallpox Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APP-0303s - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CJ-50300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell-Cultured Smallpox Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mult. mAbs/DARTs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SmallPox Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IkT-001 Pro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smallpox Therapeutics - Drug Profile Updates
Smallpox Therapeutics - Dormant Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jun 18, 2012: Bavarian Nordic Receives Contract From US Government To Advance Development Of New MVA-BN Based Vaccines
Jun 01, 2012: PharmAthene Announces Delaware Chancery Court Issues Final Order And Judgment Upholding Favorable Ruling
May 22, 2012: US Government Supports Phase III Study Of Bavarian Nordic's Smallpox Vaccine
Apr 03, 2012: Chimerix To Present Data On CMX001 At Needham And Future Leaders Conferences
Mar 01, 2012: Bavarian Nordic Submits Marketing Application For IMVAMUNE To EMA
Oct 28, 2011: Bavarian Nordic Receives $25m Milestone Payment After Scaling Up For Industrial Production Of IMVAMUNE
Oct 13, 2011: PharmAthene Submits Legal Brief In Response To SIGA Technologies's Motion For Reargument
Jun 27, 2011: SIGA To Sell 1.7 Million Courses Of ST-246 To National Stockpile Under Modified BARDA Contract

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556438&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Just Released: "Alopecia - Pipeline Review, H1 2013"

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Alopecia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alopecia. Alopecia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556442_alopecia_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Alopecia.
* A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Alopecia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Alopecia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alopecia Overview
Therapeutics Development
An Overview of Pipeline Products for Alopecia
Alopecia Therapeutics under Development by Companies
Alopecia Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Alopecia Therapeutics - Products under Development by Companies
Alopecia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Alopecia Therapeutics Development
Allergan, Inc.
AntiCancer, Inc.
Cosmo Pharmaceuticals S.p.A
Panacea Biotec Limited
R-Tech Ueno, Ltd.
AndroScience Corporation
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Kuhnil Pharmaceutical Co., Ltd.
Lee's Pharmaceutical Holdings Limited
Ascenion GmbH
OmegaGenesis, Inc.
Alopecia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HYG-430 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-420 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASCJ-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RK-023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Alopecia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipo-4MA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-03-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimatoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valproic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nanorods Topical - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KI-1104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KI-1105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P2Y5-Ligand LPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alopecia Therapeutics - Drug Profile Updates
Alopecia Therapeutics - Discontinued Products
Alopecia Therapeutics - Dormant Products
Alopecia - Product Development Milestones
Featured News & Press Releases
Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows
Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia
Apr 11, 2012: FDA Announces Changes To Professional Labels For Propecia
Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia
Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB-03-01
Oct 06, 2009: R-Tech Ueno Initiates Early Phase II Clinical Trial For RK-023
Jul 16, 2009: Notification Of The Completion Of Phase I Clinical Study Of RK-023
May 30, 2006: Banyu Pharmaceutical Confirms Efficacy of Propecia in Long-term Administration.
Mar 08, 2002: MHR Announces New Data Released on Propecia at International Live Surgery Workshop.
Dec 22, 1997: Merck's Propecia Cleared For Marketing: Once-A-Day Pill Offers Men Effective Treatment For Male Pattern Hair Loss
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Alopecia, H1 2013
Products under Development for Alopecia - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556442&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Recent Study: Macular Edema - Pipeline Review, H1 2013

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Macular Edema - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Edema. Macular Edema - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556447_macular_edema_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Scope

* A snapshot of the global therapeutic scenario for Macular Edema.
* A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Macular Edema pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Macular Edema.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Edema Overview
Therapeutics Development
An Overview of Pipeline Products for Macular Edema
Macular Edema Therapeutics under Development by Companies
Macular Edema Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Macular Edema Therapeutics - Products under Development by Companies
Macular Edema Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Macular Edema Therapeutics Development
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.
Inotek Pharmaceuticals Corporation
Taiwan Liposome Company
Pfenex Inc.
Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eylea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PARP Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-6001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trientine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-6002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab Biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macular Edema Therapeutics - Drug Profile Updates
Macular Edema Therapeutics - Discontinued Products
Macular Edema Therapeutics - Dormant Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Sep 21, 2012: Regeneron Pharma Announces FDA Approval Of Eylea Injection For Macular Edema Following Central Retinal Vein Occlusion
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Ozurdex
Jun 11, 2012: Scottish Medicines Consortium Accepts OZURDEX For Use Within NHS Scotland
Jan 13, 2012: Genentech Announces First Milestone Payment To ForSight VISION4 For Development Of Sustained Delivery Of Lucentis
Nov 24, 2011: NICE Rejects Lucentis For Treatment Of Visual Impairment Caused By Macular Oedema
Aug 03, 2011: NICE Gives Positive Recommendation To Dexamethasone For Treatment Of Common Eye Condition In Final Guidance
Jun 06, 2011: NICE Recommends Allergan's OZURDEX For Treatment Of Retinal Vein Occulsion
Jun 06, 2011: Novartis Gains European Commission Approval For Lucentis To Treat Vision Loss Due To Macular Edema Secondary To RVO
May 04, 2011: Promedior Presents Preclinical Data At ARVO Demonstrating PRM-151 Reduces Neovascularization In Retinal Diseases
Feb 11, 2011: Genentech's Lucentis Phase III Study Meets Primary Endpoint For Improving Vision In Patients With Diabetic Macular Edema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Macular Edema, H1 2013
Products under Development for Macular Edema - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
F. Hoffmann-La Roche Ltd., H1 2013
Regeneron Pharmaceuticals, Inc., H1 2013
Inotek Pharmaceuticals Corporation, H1 2013
Taiwan Liposome Company, H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556447&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Market Report, "Schizophrenia - Pipeline Review, H1 2013", published

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Schizophrenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. Schizophrenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Schizophrenia.
* A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Schizophrenia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/585776_schizophrenia_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Schizophrenia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Schizophrenia Overview
Therapeutics Development
An Overview of Pipeline Products for Schizophrenia
Schizophrenia Therapeutics under Development by Companies
Schizophrenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Schizophrenia Therapeutics - Products under Development by Companies
Schizophrenia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Schizophrenia Therapeutics Development
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
Eli Lilly and Company
GlaxoSmithKline plc
Alkermes, Inc.
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Albany Molecular Research, Inc.
Zogenix, Inc.
Neurocrine Biosciences, Inc.
Novartis AG
EnVivo Pharmaceuticals
EGIS Pharmaceuticals Plc
Gedeon Richter Plc.
H Lundbeck A/S
Les Laboratoires Servier
Pfizer Inc.
Zydus Cadila Healthcare Limited
Shire Plc
XTL Biopharmaceuticals Ltd.
NuPathe Inc.
Addex Pharmaceuticals
Evotec Aktiengesellschaft
Bionomics Limited
University of Florida
ACADIA Pharmaceuticals Inc.
Dongwha Pharm Co., Ltd.
Biotie Therapies Corp.
Allon Therapeutics Inc.
Suven Life Sciences Ltd.
Newron Pharmaceuticals S.p.A.
Mithridion, Inc.
Intas Pharmaceuticals Ltd.
Spectrum Pharmaceuticals, Inc.
CoMentis, Inc.
Snowdon Inc.
Domain Therapeutics
Critical Pharmaceuticals Limited
Curemark, LLC
Fabre-Kramer Pharmaceuticals, Inc.
PsychoGenics, Inc.
Omeros Corporation
Intra-Cellular Therapies, Inc.
Peptron, Inc.
Targacept, Inc.
N-Gene Research Laboratories, Inc.
Galenea Corp.
Marinus Pharmaceuticals, Inc.
Adamed Sp. z o.o.
KemPharm, Inc.
Heptares Therapeutics Ltd.
Ascendis Pharma A/S
Envoy Therapeutics, Inc.
Reviva Pharmaceuticals Inc.
Naurex, Inc.
PharmaNeuroBoost N.V.
Schizophrenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
davunetide - Drug Profile
AQW-051 - Drug Profile
GSK-239512 - Drug Profile
GTS-21 - Drug Profile
ADX-63365 - Drug Profile
zicronapine - Drug Profile
lurasidone hydrochloride - Drug Profile
lurasidone hydrochloride - Drug Profile
lurasidone hydrochloride - Drug Profile
AMG-747 - Drug Profile
TC-5619 - Drug Profile
PDE10a Inhibitors - Drug Profile
brexpiprazole - Drug Profile
cariprazine hydrochloride - Drug Profile
cariprazine hydrochloride - Drug Profile
cariprazine hydrochloride - Drug Profile
ADX-71149 - Drug Profile
AM-831 - Drug Profile
TGOF-02N - Drug Profile
OMS-824 - Drug Profile
neboglamine - Drug Profile

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=585776&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


New Market Report: Fatigue - Pipeline Review, H1 2013

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Fatigue - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. Fatigue - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/585785_fatigue_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Scope

* A snapshot of the global therapeutic scenario for Fatigue.
* A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Fatigue pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Fatigue.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatigue Overview
Therapeutics Development
An Overview of Pipeline Products for Fatigue
Fatigue Therapeutics under Development by Companies
Fatigue Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Fatigue Therapeutics - Products under Development by Companies
Fatigue Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Fatigue Therapeutics Development
Sanofi-Aventis
Galenica Ltd.
Sigma-Tau S.p.A.
Hemispherx Biopharma, Inc.
MultiCell Technologies, Inc.
Alder Biopharmaceuticals Inc.
Adamas Pharmaceuticals, Inc.
Biolab Farmaceutica
Fatigue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
clazakizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(lofepramine + phenylalanine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levocarnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levocarnitine + piracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fatigue Therapeutics - Drug Profile Updates
Fatigue Therapeutics - Discontinued Products
Fatigue Therapeutics - Dormant Products
Fatigue - Product Development Milestones
Featured News & Press Releases
Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012
Sep 24, 2012: Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen For Chronic Fatigue Syndrome
Aug 14, 2012: FDA Accepts Complete Response Submission Regarding Ampligen New Drug Application For Chronic Fatigue Syndrome
Aug 01, 2012: Hemispherx Files Complete Response With FDA Regarding Ampligen NDA For Chronic Fatigue Syndrome
Jul 18, 2012: Hemispherx Biopharma Files New Drug Application In Argentina For Ampligen To Treat Chronic Fatigue Syndrome
Jul 11, 2012: Hemispherx And FDA Reach Agreement On Filing Requirements For Complete Response In Support Of Ampligen NDA For Chronic Fatigue Syndrome Treatment
Apr 17, 2012: Galenica Announces Results Of Ferinject Clinical Study
Mar 19, 2012: Hemispherx Publishes Data On Bioactivity Of Ampligen In Chronic Fatigue Syndrome
Jan 11, 2012: FDA Grants Hemispherx Extension In Its Pending New Drug Application For Treatment Of Chronic Fatigue Syndrome
Dec 14, 2010: Hemispherx Receives FDA Extension For Pending NDA Of Chronic Fatigue Syndrome Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Fatigue, H1 2013
Products under Development for Fatigue - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Sanofi-Aventis, H1 2013
Galenica Ltd., H1 2013
Sigma-Tau S.p.A., H1 2013
Hemispherx Biopharma, Inc., H1 2013
MultiCell Technologies, Inc., H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=585785&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


"Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013" Published

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections). Meningococcemia (Meningococcal Infections) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/585806_meningococcemia_meningococcal_infections_pipeline.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Meningococcemia (Meningococcal Infections).
* A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningococcemia (Meningococcal Infections) Overview
Therapeutics Development
An Overview of Pipeline Products for Meningococcemia (Meningococcal Infections)
Meningococcemia (Meningococcal Infections) Therapeutics under Development by Companies
Meningococcemia (Meningococcal Infections) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Meningococcemia (Meningococcal Infections) Therapeutics - Products under Development by Companies
Meningococcemia (Meningococcal Infections) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Meningococcemia (Meningococcal Infections) Therapeutics Development
GlaxoSmithKline plc
Pfizer Inc.
Panacea Biotec Limited
Serum Institute of India Limited
Meningococcemia (Meningococcal Infections) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Meninge ACYW Conjugate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MnB rLP2086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PsA-TT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-134612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Haemophilus influenzae type b and meningococcal serogroup C (vaccine) + Priorix + Hiberix + Meningitec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Conjugated Meningococcal C Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rLP2086 + MCV4 + Tdap - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCV4 + Tdap - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rLP-2086 + Gardasil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kingella Kingae Outer Membrane Vesicles Based Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningococcal Group B Recombinant Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meningococcemia (Meningococcal Infections) Therapeutics - Drug Profile Updates
Meningococcemia (Meningococcal Infections) Therapeutics - Dormant Products
Meningococcemia (Meningococcal Infections) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers
Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants
Dec 23, 2010: Novartis Submits Meningococcal B Vaccine For Regulatory Review In Europe
Appendix

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=585806&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Report Published: "Cervical Dysplasia - Pipeline Review, H1 2013"

0
0

(PRBuzz.com) April 16, 2013 -- Global Markets Direct's, 'Cervical Dysplasia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Dysplasia. Cervical Dysplasia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/585819_cervical_dysplasia_pipeline_review_h1_2013.aspx?afid=101
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Cervical Dysplasia.
* A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cervical Dysplasia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cervical Dysplasia Overview
Therapeutics Development
An Overview of Pipeline Products for Cervical Dysplasia
Cervical Dysplasia Therapeutics under Development by Companies
Cervical Dysplasia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Cervical Dysplasia Therapeutics - Products under Development by Companies
Cervical Dysplasia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cervical Dysplasia Therapeutics Development
Photocure ASA
Inovio Biomedical Corporation
Advaxis, Inc.
AnGes MG, Inc.
Cervical Dysplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
VGX-3100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADXS-HPV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hexaminolevulinate hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Bicarbonate + Lidocain + Epinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cervical Dysplasia Therapeutics - Drug Profile Updates
Cervical Dysplasia Therapeutics - Discontinued Products
Cervical Dysplasia Therapeutics - Dormant Products
Cervical Dysplasia - Product Development Milestones
Featured News & Press Releases
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study
Jun 07, 2012: Advaxis Completes Enrollment Of Cohort 2 In Phase II CIN 2/3 Study
May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer
Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress
Jul 25, 2011: Advaxis Revises Protocol For CIN Study
Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
Jul 11, 2011: Advaxis Completes Enrollment Of Low Dose Cohort In CIN Study
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cervical Dysplasia, H1 2013
Products under Development for Cervical Dysplasia - Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=585819&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.



New Market Research Report: Property Insurance in Estonia to 2017: Market Databook

0
0

(PRBuzz.com) April 16, 2013 -- This report is the result of Timetric's extensive market research covering the non-life insurance industry in Estonia. It contains detailed historic and forecast data for property insurance. 'Property Insurance in Estonia to 2017: Market Databook' provides detailed insight into the operating environment of the non-life insurance industry in Estonia. It is an essential tool for companies active across the Estonian non-life insurance value chain and for new players considering to enter the market.

Scope

* Historic and forecast data for property insurance in the non-life insurance industry in Estonia for the period 2008 through to 2017
* Historic and forecast data on gross written premiums, earned premiums, number of active policies, number of schemes offered, insurance penetration percentage, gross claims, paid claims, change in outstanding reserves, incurred loss, loss ratio percentage and density and penetration for the period 2008 through to 2017

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556507_property_insurance_in_estonia_to_2017_market.aspx?afid=101
------------------------------------------------------------

Reasons to Purchase

* This report provides you with valuable data for the non-life insurance industry covering property insurance in Estonia
* This report provides you with a breakdown of market data including data on gross written premiums, earned premiums, number of active policies, number of schemes offered, insurance penetration percentage, gross claims, paid claims, change in outstanding reserves, incurred loss, loss ratio percentage and density and penetration
* This report allows you to plan future business decisions using the forecast figures given for the market

Partial Table of Contents:

1 INTRODUCTION
1.1 What is this Report About?
1.2 Definitions
2 POLICIES AND PREMIUMS
2.1 Gross Written Premiums
2.2 Gross Written Premiums Forecast
2.3 Earned Premiums
2.4 Earned Premium Forecast
2.5 Number of Active Policies
2.6 Number of Active Policies Forecast
2.7 Number of Schemes Offered
2.8 Number of Schemes Offered Forecast
2.9 Insurance Penetration (% of GDP)
2.10 Insurance Penetration (% of GDP) Forecast
3 CLAIMS AND EXPENSES
3.1 Gross Claims
3.2 Gross Claims Forecast
3.3 Paid Claims
3.4 Paid Claims Forecast
3.5 Change in Outstanding Reserves
3.6 Change in Outstanding Reserves Forecast
3.7 Incurred Loss
3.8 Incurred Loss Forecast
3.9 Loss Ratio %
3.10 Loss Ratio % Forecast
4 FIRE AND ALLIED PERILS
4.1 Number of Active Policies
4.2 Number of Active Policies Forecast
4.3 Gross Written Premiums
4.4 Gross Written Premiums Forecast
4.5 Insurance Density and Penetration
4.6 Insurance Density and Penetration Forecast
5 ENGINEERING
5.1 Number of Active Policies
5.2 Number of Active Policies Forecast
5.3 Gross Written Premiums
5.4 Gross Written Premiums Forecast
5.5 Insurance Density and Penetration
5.6 Insurance Density and Penetration Forecast
6 AGRICULTURE
6.1 Number of Active Policies
6.2 Number of Active Policies Forecast
6.3 Gross Written Premiums
6.4 Gross Written Premiums Forecast
6.5 Insurance Density and Penetration
6.6 Insurance Density and Penetration Forecast
7 OTHER PROPERTY INSURANCE
7.1 Number of Active Policies
7.2 Number of Active Policies Forecast
7.3 Gross Written Premiums
7.4 Gross Written Premiums Forecast
7.5 Insurance Density and Penetration
7.6 Insurance Density and Penetration Forecast
8 APPENDIX
8.1 Methodology
8.2 Contact Us
8.3 About Timetric
8.4 Our Services
8.5 Disclaimer

List of Tables

Table 1: Insurance Industry Definitions
Table 2: Estonian Property Insurance; Gross Written Premiums (US$ Billion), 2008-2012
Table 3: Estonian Property Insurance; Gross Written Premiums (EUR Billion), 2008-2012
Table 4: Estonian Property Insurance; Gross Written Premiums (US$ Billion), 2012-2017
Table 5: Estonian Property Insurance; Gross Written Premiums (EUR Billion), 2012-2017
Table 6: Estonian Property Insurance; Earned Premiums (US$ Billion), 2008-2012
Table 7: Estonian Property Insurance; Earned Premiums (EUR Billion), 2008-2012
Table 8: Estonian Property Insurance; Earned Premiums (US$ Billion), 2012-2017
Table 9: Estonian Property Insurance; Earned Premiums (EUR Billion), 2012-2017
Table 10: Estonian Property Insurance; Number of Active Policies (Million), 2008-2012
Table 11: Estonian Property Insurance; Number of Active Policies (Million), 2012-2017
Table 12: Estonian Property Insurance; Number of Schemes Offered (Absolute), 2008-2012
Table 13: Estonian Property Insurance; Number of Schemes Offered (Absolute), 2012-2017
Table 14: Estonian Property Insurance; Insurance Penetration (% of GDP), 2008-2012
Table 15: Estonian Property Insurance; Insurance Penetration (% of GDP), 2012-2017
Table 16: Estonian Property Insurance; Gross Claims (US$ Billion), 2008-2012
Table 17: Estonian Property Insurance; Gross Claims (EUR Billion), 2008-2012
Table 18: Estonian Property Insurance; Gross Claims (US$ Billion), 2012-2017
Table 19: Estonian Property Insurance; Gross Claims (EUR Billion), 2012-2017
Table 20: Estonian Property Insurance; Paid Claims (US$ Billion), 2008-2012
Table 21: Estonian Property Insurance; Paid Claims (EUR Billion), 2008-2012
Table 22: Estonian Property Insurance; Paid Claims (US$ Billion), 2012-2017
Table 23: Estonian Property Insurance; Paid Claims (EUR Billion), 2012-2017
Table 24: Estonian Property Insurance; Change in Outstanding Reserves (US$ Billion), 2008-2012
Table 25: Estonian Property Insurance; Change in Outstanding Reserves (EUR Billion), 2008-2012
Table 26: Estonian Property Insurance; Change in Outstanding Reserves (US$ Billion), 2012-2017
Table 27: Estonian Property Insurance; Change in Outstanding Reserves (EUR Billion), 2012-2017
Table 28: Estonian Property Insurance; Incurred Loss (US$ Billion), 2008-2012

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=556507&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.comhttp://www.fastmr.com or call us at 1.800.844.8156.


Life Insurance Claims and Expenses in Burkina Faso to 2017: Market Databook - New Report Available

0
0

(PRBuzz.com) April 16, 2013 -- This report is the result of Timetric's extensive market research covering the life insurance industry in Burkina Faso. It contains detailed historic and forecast data for claims and expenses. 'Life Insurance Claims and Expenses in Burkina Faso to 2017: Market Databook' provides detailed insight into the operating environment of the life insurance industry in Burkina Faso. It is an essential tool for companies active across the Burkinese life insurance value chain and for new players considering to enter the market.

Scope

* Historic and forecast data for claims and expenses in the life insurance industry in Burkina Faso for the period 2008 through to 2017
* Historic and forecast data on gross claims, paid claims, incurred loss, loss ratio percentage and combined ratio percentage for the period 2008 through to 2017

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556561_life_insurance_claims_and_expenses_in_burkina.aspx?afid=101
------------------------------------------------------------

Reasons to Purchase

* This report provides you with valuable data for the life insurance industry covering claims and expenses in Burkina Faso
* This report provides you with a breakdown of market data including data on gross claims, paid claims, incurred loss, loss ratio percentage and combined ratio percentage
* This report allows you to plan future business decisions using the forecast figures given for the market

Report Table of Contents:

1 INTRODUCTION
1.1 What is this Report About?
1.2 Definitions
2 INDUSTRY ANALYSIS
2.1 Gross Claims
2.2 Gross Claims Forecast
2.3 Paid Claims
2.4 Paid Claims Forecast
2.5 Incurred Loss
2.6 Incurred Loss Forecast
2.7 Loss Ratio %
2.8 Loss Ratio % Forecast
2.9 Combined Ratio %
2.10 Combined Ratio % Forecast
3 APPENDIX
3.1 Methodology
3.2 Contact Us
3.3 About Timetric
3.4 Our Services
3.5 Disclaimer

List of Tables

Table 1: Insurance Industry Definitions
Table 2: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (US$ Billion), 2008-2012
Table 3: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (XOF Billion), 2008-2012
Table 4: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (US$ Billion), 2012-2017
Table 5: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (XOF Billion), 2012-2017
Table 6: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (US$ Billion), 2008-2012
Table 7: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (XOF Billion), 2008-2012
Table 8: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (US$ Billion), 2012-2017
Table 9: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (XOF Billion), 2012-2017
Table 10: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2008-2012
Table 11: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (XOF Billion), 2008-2012
Table 12: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2012-2017
Table 13: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (XOF Billion), 2012-2017
Table 14: Burkina Faso Life Insurance Claims and Expenses; Loss Ratio % (Percentage), 2008-2012
Table 15: Burkina Faso Life Insurance Claims and Expenses; Loss Ratio % (Percentage ), 2012-2017
Table 16: Burkina Faso Life Insurance Claims and Expenses; Combined Ratio % (Percentage), 2008-2012
Table 17: Burkina Faso Life Insurance Claims and Expenses; Combined Ratio % (Percentage), 2012-2017

List of Figures

Figure 1: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (US$ Billion), 2008-2012
Figure 2: Burkina Faso Life Insurance Claims and Expenses; Gross Claims (US$ Billion), 2012-2017
Figure 3: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (US$ Billion), 2008-2012
Figure 4: Burkina Faso Life Insurance Claims and Expenses; Paid Claims (US$ Billion), 2012-2017
Figure 5: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2008-2012
Figure 6: Burkina Faso Life Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2012-2017
Figure 7: Burkina Faso Life Insurance Claims and Expenses; Loss Ratio % (Percentage), 2008-2012
Figure 8: Burkina Faso Life Insurance Claims and Expenses; Loss Ratio % (Percentage ) 2012-2017
Figure 9: Burkina Faso Life Insurance Claims and Expenses; Combined Ratio % (Percentage), 2008-2012
Figure 10: Burkina Faso Life Insurance Claims and Expenses; Combined Ratio % (Percentage),2012-2017

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Personal Accident and Health Insurance Claims and Expenses in Albania to 2017: Market Databook

0
0

(PRBuzz.com) April 16, 2013 -- This report is the result of Timetric's extensive market research covering the personal accident and health insurance industry in Albania. It contains detailed historic and forecast data for claims and expenses. 'Personal Accident and Health Insurance Claims and Expenses in Albania to 2017: Market Databook' provides detailed insight into the operating environment of the personal accident and health insurance industry in Albania. It is an essential tool for companies active across the Albanian personal accident and health insurance value chain and for new players considering to enter the market.

Scope

* Historic and forecast data for claims and expenses in the personal accident and health insurance industry in Albania for the period 2008 through to 2017
* Historic and forecast data on gross claims, paid claims, incurred loss, loss ratio percentage and combined ratio percentage for the period 2008 through to 2017

Reasons to Purchase

* This report provides you with valuable data for the personal accident and health insurance industry covering claims and expenses in Albania
* This report provides you with a breakdown of market data including data on gross claims, paid claims, incurred loss, loss ratio percentage and combined ratio percentage
* This report allows you to plan future business decisions using the forecast figures given for the market

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/556568_personal_accident_and_health_insurance_claims_and.aspx?afid=101
------------------------------------------------------------

Report Table of Contents:

1 INTRODUCTION
1.1 What is this Report About?
1.2 Definitions
2 INDUSTRY ANALYSIS
2.1 Gross Claims
2.2 Gross Claims Forecast
2.3 Paid Claims
2.4 Paid Claims Forecast
2.5 Incurred Loss
2.6 Incurred Loss Forecast
2.7 Loss Ratio %
2.8 Loss Ratio % Forecast
2.9 Combined Ratio %
2.10 Combined Ratio % Forecast
3 APPENDIX
3.1 Methodology
3.2 Contact Us
3.3 About Timetric
3.4 Our Services
3.5 Disclaimer

List of Tables

Table 1: Insurance Industry Definitions
Table 2: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (US$ Billion), 2008-2012
Table 3: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (ALL Billion), 2008-2012
Table 4: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (US$ Billion), 2012-2017
Table 5: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (ALL Billion), 2012-2017
Table 6: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (US$ Billion), 2008-2012
Table 7: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (ALL Billion), 2008-2012
Table 8: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (US$ Billion), 2012-2017
Table 9: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (ALL Billion), 2012-2017
Table 10: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2008-2012
Table 11: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (ALL Billion), 2008-2012
Table 12: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2012-2017
Table 13: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (ALL Billion), 2012-2017
Table 14: Albanian Personal Accident & Health Insurance Claims and Expenses; Loss Ratio % (Percentage), 2008-2012
Table 15: Albanian Personal Accident & Health Insurance Claims and Expenses; Loss Ratio % (Percentage ), 2012-2017
Table 16: Albanian Personal Accident & Health Insurance Claims and Expenses; Combined Ratio % (Percentage), 2008-2012
Table 17: Albanian Personal Accident & Health Insurance Claims and Expenses; Combined Ratio % (Percentage), 2012-2017

List of Figures

Figure 1: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (US$ Billion), 2008-2012
Figure 2: Albanian Personal Accident & Health Insurance Claims and Expenses; Gross Claims (US$ Billion), 2012-2017
Figure 3: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (US$ Billion), 2008-2012
Figure 4: Albanian Personal Accident & Health Insurance Claims and Expenses; Paid Claims (US$ Billion), 2012-2017
Figure 5: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2008-2012
Figure 6: Albanian Personal Accident & Health Insurance Claims and Expenses; Incurred Loss (US$ Billion), 2012-2017
Figure 7: Albanian Personal Accident & Health Insurance Claims and Expenses; Loss Ratio % (Percentage), 2008-2012
Figure 8: Albanian Personal Accident & Health Insurance Claims and Expenses; Loss Ratio % (Percentage ) 2012-2017
Figure 9: Albanian Personal Accident & Health Insurance Claims and Expenses; Combined Ratio % (Percentage), 2008-2012
Figure 10: Albanian Personal Accident & Health Insurance Claims and Expenses; Combined Ratio % (Percentage),2012-2017

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Report Published: "The Insurance Industry in El Salvador, Key Trends and Opportunities to 2017"

0
0

(PRBuzz.com) April 16, 2013 -- The Salvadoran insurance industry is the fourth-largest in Central America after Panama, Costa Rica and Guatemala. Led by economic recovery, the country's insurance industry's gross written premium registered a moderate CAGR of 3.2% during the review period. Over the forecast period, growing investment in infrastructure in collaboration with the US, an improving business environment, new product developments and rising healthcare expenditure will support the growth of the insurance industry.

Key Highlights

* Government-planned investment in infrastructure is considered key to restoring economic growth and creating job opportunities in El Salvador
* The penetration (measured by gross written premiums as a percentage of GDP) of the Salvadoran insurance industry is lower than other countries in Central America
* The Salvadoran insurance industry is highly competitive with 21 active insurance companies at the end of 2012
* The introduction of compulsory third-party motor insurance, which was originally scheduled to come into force on May 20, 2009, has been delayed
* The country's proximity to Latin America and the US enables Salvadoran insurers to underwrite policies directly from these areas
* The frequency of natural disasters is likely to further improve awareness of the need for insurance products in the coming years

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/584439_the_insurance_industry_in_el_salvador_key_trends.aspx?afid=101
------------------------------------------------------------

Scope

This report provides a comprehensive analysis of the insurance industry in El Salvador:

* It provides historical values for the Salvadoran insurance industry for the report's 2008-2012 review period and forecast figures for the 2012-2017 forecast period
* It offers a detailed analysis of the key segments and categories in the Salvadoran insurance industry, along with industry forecasts until 2017
* It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, total assets, total investment income and retentions
* It profiles the top insurance companies in El Salvador and outlines the key regulations affecting them

Reasons to Purchase

* Make strategic business decisions using in depth historic and forecast industry data related to the Salvadoran insurance industry and each segment within it
* Assess the competitive dynamics in the Salvadoran insurance industry
* Understand the demand-side dynamics, key market trends and growth opportunities within the Salvadoran insurance industry
* Identify the growth opportunities and market dynamics within key segments
* Gain insights into key regulations governing the Salvadoran insurance industry and its impact on companies and the industry's future

Companies Mentioned in this Report: Aseguradora Agricola Comercial, SA, Sisa Vida SA, La Centro Americana, SA, Asesuisa Vida, SA Seguros de Personas, Scotia Seguros, SA

Partial Table of Contents:

1 Executive Summary
2 Introduction
2.1 What is this Report About?
2.2 Definitions
2.3 Methodology
3 The Salvadoran Insurance Industry Overview
3.1 The Salvadoran Insurance Industry
3.2 Key Industry Trends and Drivers
3.3 Challenges
3.4 Regulation
4 Industry Segmentation
4.1 Life Insurance
4.2 Non-Life Insurance
4.2.1 Property insurance
4.2.2 Motor insurance
4.2.3 Marine, aviation and transit insurance
4.3 Personal Accident and Health Insurance
5 Competitive Landscape
5.1 Overview
5.2 Leading Companies
5.2.1 Aseguradora Agricola Comercial, SA - Company overview
5.2.2 Sisa Vida SA - Company overview
5.2.3 La Centro Americana, SA - Company overview
5.2.4 Asesuisa Vida, SA Seguros de Personas - Company overview
5.2.5 Scotia Seguros, SA - Company overview
6 Macroeconomic Indicators
6.1 GDP at Constant Prices (US Dollars)
6.2 GDP per Capita at Constant Prices (US Dollars)
6.3 GDP at Current Prices (US Dollars)
6.4 Inflation
6.5 Exports as a Percentage of GDP
6.6 Construction Output (US Dollar)
6.7 Unemployment as percentage of total labor force
6.8 Life expectancy
6.9 Healthcare Expenditure per Capita
6.1 Healthcare Expenditure percentage of GDP
6.11 Annual Household Consumption Expenditure
6.12 Total Population
7 Appendix
7.1 Methodology
7.2 Contact Us
7.3 About Timetric
7.4 Disclaimer

List of Tables

Table 1: Insurance Industry Definitions
Table 2: Salvadoran Insurance Industry - Overall Written Premium by Segment (US$ Million), 2008-2012
Table 3: Salvadoran Insurance Industry - Overall Written Premium by Segment (US$ Million), 2012-2017
Table 4: Salvadoran Insurance Industry - Segmentation (% Share), 2008-2017
Table 5: Salvadoran Life Insurance - Written Premium (US$ Million), 2008-2012
Table 6: Salvadoran Life Insurance - Written Premium (US$ Million), 2012-2017
Table 7: Salvadoran Life Insurance - Paid Claims (US$ Million), 2008-2012
Table 8: Salvadoran Life Insurance - Paid Claims (US$ Million), 2012-2017
Table 9: Salvadoran Life Insurance - Incurred Loss (US$ Million), 2008-2012
Table 10: Salvadoran Life Insurance - Incurred Loss (US$ Million), 2012-2017
Table 11: Salvadoran Life Insurance - Loss Ratio (%), 2008-2012
Table 12: Salvadoran Life Insurance - Loss Ratio (%), 2012-2017
Table 13: Salvadoran Life Insurance - Combined Ratio (%), 2008-2012
Table 14: Salvadoran Life Insurance - Combined Ratio (%), 2012-2017
Table 15: Salvadoran Life Insurance - Retentions (US$ Million), 2008-2012
Table 16: Salvadoran Life Insurance - Retentions (US$ Million), 2012-2017
Table 17: Salvadoran Non-Life Insurance - Written Premium by Category (US$ Million),
Table 18: Salvadoran Non-Life Insurance - Written Premium by Category (US$ Million),
Table 19: Salvadoran Non-Life Insurance - Paid Claims (US$ Million), 2008-2012
Table 20: Salvadoran Non-Life Insurance - Paid Claims (US$ Million), 2012-2017
Table 21: Salvadoran Non-Life Insurance - Incurred Loss (US$ Million), 2008-2012
Table 22: Salvadoran Non-Life Insurance - Incurred Loss (US$ Million), 2012-2017
Table 23: Salvadoran Non-Life Insurance - Loss Ratio (%), 2008-2012
Table 24: Salvadoran Non-Life Insurance - Loss Ratio (%), 2012-2017

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=584439&dt=t&afid=101

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Nutritional Sciences Now Provides the Best Fat Burning Supplement Garcinia Cambogia Through Amazon

0
0

New York, NY (PRBuzz.com) April 16, 2013 -- Nutritional Sciences, a company dedicated in providing various natural supplements, is now offering the No. 1 fat burning supplement Garcinia Cambogia through Amazon.com. The natural supplement whose sales have skyrocketed after featuring in the Dr. Oz Show is regarded as highly effective and 100% side effects free. Garcinia Cambogia is considered to be the best fat burning supplement ever and its number of consumers is increasing worldwide.

The media spokesperson of the company quoted on the reason behind Garcinia Cambogia's success, "Finding a weight loss supplement that is 100% natural yet fairly effective has been a product that all leading manufacturers have been trying to find. With the discovery of the Garcinia extract finally a supplement was created to cater all weight loss needs without worrying about the side effects. However the absence of side effects is not the only factor behind the popularity of the natural supplement but also its effectiveness, where reports have shown that nearly 3 times more weight can be lost by using the supplement along with regular diet and exercise."

The supplement according to health professionals acts as a fat blocker by controlling overeating, sugar cravings and emotional eating. Garcinia Cambogia also helps burn an enzyme called Citrate Lyase, which causes the body to turn excess carbohydrates into fat. This collaborative effect of suppressing appetite and blocking fat in a natural manner has resulted in the supplement's effectiveness and worldwide popularity.

Nutritional Sciences is currently offering Garcinia Lean - Garcinia Cambogia at a 40% discount through Amazon.com. The company has already established itself as a premier provider of natural supplements only. Pure Garcinia Cambogia is their best selling product and has received exceptional reviews from health critics and consumers alike. The company like always is also offering a 100% money back guarantee. Interested individuals who would like to buy Garcinia Cambogia can visit Amazon.com and view further details. Amazon is providing free shipping on all purchases of Garcinia Lean - Garcinia Cambogia.


About Nutritional Sciences
Nutritional Sciences is one of the leading companies in providing various natural supplements. The company has been providing supplements for over 14 years and through their online platform, http://www.nutritionalsciences.com/, the natural supplements offered by them can be viewed. Nutritional Sciences supplements are known for being highly effective and safe.

###

For more information about Garcinia Cambogia, or to schedule a meeting or interview with founders of nutritionalsciences.com, please call at (482) 472-1821 or email to stevethompson@nutritionalsciences.com.

English Premier League to rise parachute payments for relegated clubs

0
0

(PRBuzz.com) April 16, 2013 -- Football clubs that suffer relegation from the English Premier League will receive around £60m over a four-year period.

The Premier League is yet to confirm the exact figure, while the issue of solidarity payments to the Football League clubs is still to be finalized.

Parachute payments are distributed to relegated teams to soften the financial blow of demotion to the Championship, where TV and sponsorship revenue is hugely reduced.

The Premier League reportedly planned to stop solidarity payments, a figure distributed among the 72 clubs in the Football League, if those clubs rejected the proposal.

The revised payments meant that instead of clubs relegated from the Premier League receiving £16m a year for two years, they received £48m spread over four years -£16m per season for the first two seasons, then a further two payments of £8m per season.

Reading and Queens Park Rangers look certain to be among the first beneficiaries of the new deal, with both stranded at the bottom of the Premier League table. The third relegation place is currently being occupied by Wigan Athletic, but Aston Villa, Stoke City, Sunderland, Norwich and Newcastle United remain in danger.

-------------------------------------------------------

About Live Football Tickets .com: Thousands of soccer tickets are on sale on Europe's biggest football ticketing website: LiveFootballTickets.com. We have Premier League tickets available online.

Media Contact:
Christopher J. Brown
LiveFootballTickets.com
Ph: +44 207 060 5277
marketing[at]livefootballtickets.com

Plainview, NY Dentist Mark Bram of Bram Dental Emphasizes the Importance of Oral Cancer Screenings

0
0

Dr. Mark Bram
Bram Dental
www.bramdental.com
516-681-3322

Plainview, NY Dentist Mark Bram of Bram Dental Emphasizes the Importance of Oral Cancer Screenings

(PRBuzz.com) April 16, 2013 -- Throughout the year we undergo various health tests and screenings to make sure that we are staying on top of our health. These tests are preventative measures that leave patients with peace of mind or a serious advantage in finding an effective treatment. While we know that we have to monitor our blood pressure, stress, weight, hearing, sight and other health concerns, many forget to visit the dentist for oral cancer screenings. Dr. Mark Bram offers oral screenings at Bram Dental in Plainview, NY. He encourages all older adults to visit his office for a complete regular oral cancer screening to improve their health.

Oral cancer is commonly identified by a tumor or growth that arises within the oral cavity. These malignancies can occur anywhere on the mouth, tongue, lips, cheeks, soft palate, hard palate, pharynx and sinuses. In the earliest stages of oral cancer, you may experience bumps, swelling or rough spots on the lips, and difficulty when moving your jaw or tongue. However, early detection at Bram Dental means that you can treat oral cancer before these symptoms fully develop or become problematic.

Dr. Mark Bram stresses the importance of undergoing an oral cancer screening at his practice. Every year about 35,000 people are diagnosed with oral cancer. When patients keep track of their health through oral cancer screenings, they lessen their risk of developing advanced stages of oral cancer. By treating the symptoms and addressing the problem early on, treatments can be administered promptly and the likelihood of recovery greatly increases. With oral cancer screenings offered by Dr. Mark Bram, Plainview, NY patients can have oral cancer diagnosed in its earliest stages and can prevent a potentially life-threatening issue from affecting the quality of their life.

For more information on oral cancer screenings, visit www.bramdental.com or call 516-681-3322 to schedule an appointment with Dr. Mark Bram at Bram Dental in Plainview, NY.


Astre Valley Appliance Service Tech in Wayne NJ Recommends Surge Protection

0
0

As modern day appliances evolve with advanced technology making them more valuable and expensive, protecting them from power surges becomes priority

Wayne NJ (PRBuzz.com) April 16, 2013 -- The local appliance repair man addresses an important concern with newer appliances. Modern day home appliances have quickly evolved with advances in technology making them more efficient. New features with high end appliances are convenient, the appliance is more valuable and more expensive to purchase.

The service technicians with Astre Valley Appliance Repair recommend surge protection for all home appliances. A simple brown out or power spike can cause damage to electrical components and result in an expensive appliance repair service. Brown outs and power spikes can occur without being noticed.

Even a well maintained appliance needs surge protection. Appliance maintenance is vital to the mechanical components and efficient performance but it doesn't protect it from power surges. The local appliance repair man suggests having a dedicated breaker and surge protector for each appliance.

Astre Valley Appliance Repair is family owned and operated and has been serving residents in Northern New Jersey for over half a century! Since opening the business in 1956, three generations of customers have enjoyed being treated like family. Astre Valley Appliance Service technicians care deeply and value their customers' patronage as they strive to give them the best service possible.

Astre Valley Appliance Repair challenges the competition by offering a full 2 year guarantee on parts and labor on all appliance repair services performed. They do not charge an additional service charge when they perform service and they use only OEM original manufacturer parts direct from the factory. Visit http://www.njappliancerepairs.com/ to learn more.

About Astre Valley Appliance Repair:
Astre Valley Appliance Repair is the premier source for the finest appliance service in Northern New Jersey. The family owned business was founded in 1956 on the highest standards of customer service. Excellence is a family tradition carried on by Astre Valley Appliance Repair family as they extend personal service to each and every client they work with.

Contact:

Maddie Moscatello
Astre Valley Appliance Service
376 Hollywood Ave
Fairfield, NJ 07004
Tel: 1-800-522-4134
Email: Service@valeyappliancenj.com

This press release was submitted by Right Now Marketing Group, LLC

Dania, FL's Brighten Dental Care Restores Patient Smiles with Full Dental Implants and Mini Implants

0
0

Brighten Dental Care
954-922-4633
www.brightendentalcare.com

Dania, FL's Brighten Dental Care Restores Patient Smiles with Full Dental Implants and Mini Implants

(PRBuzz.com) April 16, 2013 -- When many people have a missing or extracted tooth, they are concerned about the cosmetic appearance of their smile. However, smile gaps are put your mouth at risk of developing a number of periodontal issues. This includes infection, bone loss, bite misalignment and many other issues that compromise the health of your smile. Brighten Dental Care offers a solution to all patients with smile gaps and those that are looking for a more secure, comfortable and effective restoration. Dental implants are a natural looking tooth prosthetic that provide Dania, FL patients with an aesthetically beautiful smile and improved oral health.

Unlike other tooth prosthetics, dental implants are a permanent part of your smile. With proper care, dental implants can last a lifetime. Brighten Dental Care offers both full dental implants and mini implants to their Dania, FL patients. Both restorations do not require any modifications to your surrounding teeth and can be placed anywhere within the mouth. Dental implants can be used to replace a single missing tooth or all of them for a complete smile makeover. The best part of dental implants is that they look and feel like natural, real teeth. There is no special oral care necessary beyond regular brushing and flossing. Mini implants differ from full implants in that they are much smaller in size. Mini implants are great for securing other restorative dental solutions like dentures in place. Mini implants keep your dentures from slipping and sliding out of place, leaving you confident when smiling, eating and talking to friends.

Both full implants and mini implants are both rooted to the jawbone, creating the most natural look and feel of all dental restorations. It takes about three to six months for the entire dental implant process to be completed. As the implant heals, the jaw bone conforms around it, creating the realistic feel that Dania, FL patients love. Brighten Dental Care encourages patients to visit their practice for a beautiful, brand new smile.

For more information on full dental implants and mini implants, visit www.brightendentalcare.com or call 954-922-4633 to schedule an appointment at Brighten Dental Care in Dania, FL.

Dishwasher Maintenance Tips are Included in the Service by Astre Valley Appliance Repair Parsippany

0
0

Proper maintenance keeps the dishwasher clean and free from bacteria caused by debris build up which clogs the machine

Parsippany NJ (PRBuzz.com) April 16, 2013 -- The early dishwashers invented in the 1800's were simple wooden machines with a hand-turned wheel that splashed water on dishes. This was he humble beginning that led to many advancements over the years. Owning a dishwasher started becoming popular in the 1950s and has grown to become a standard household appliance.

Today's dishwashers are available in different sizes and styles to function in every home. Some of the most popular high-end brands include Fisher, Paykel, KitchenAid and Bosch. With custom panels the dishwasher blends nicely into the kitchen cabinetry with a clean, sleek design. The local dishwasher repair man says keeping the unit clean on the outside is important maintenance, but even more important is the inside. A dirty dishwasher that produces foul odors cannot be getting dishes clean.

Service technicians with Astre Valley Appliance Repair offer dishwasher maintenance tips to customers while servicing the appliance. The dishwasher repair man suggests cleaning the spray arms to remove blockages where bacteria can grow. The easiest way to maintain spray arms is to remove them and run wire through each of the holes to remove obstructions. Rinse with hot water and vinegar then reinstall.

The final step is to run the dishwasher empty, with no detergent or dishes. Just use vinegar which is an acid that will clean germs and bacteria that grows in standing water left inside the dishwasher. The acid in the vinegar will also help clear the drain.

Proper maintenance is vital to appliance function. All home appliances require maintenance to prevent break down and promote efficient performance. Some appliances require maintenance for safety issues. Well maintained appliances will perform better and last longer.

Residents in Northern New Jersey enjoy superior service by highly qualified and professional appliance service technicians. The 2 year guarantee and free return visit if anything goes wrong with the appliance within 30 days of service provides customers peace of mind that they are in good hands.

Astre Valley Appliance Repair is the leading appliance service provider in Northern NJ with over 50 years experience and an emphasis on customer service and satisfaction. Visit http://www.njappliancerepairs.com/ to learn more.

About Astre Valley Appliance Repair:
Astre Valley Appliance Repair is the premier source for the finest appliance service in Northern New Jersey. The family owned business was founded in 1956 on the highest standards of customer service. Excellence is a family tradition carried on by Astre Valley Appliance Repair family as they extend personal service to each and every client they work with.

Contact:

Maddie Moscatello
Astre Valley Appliance Service
376 Hollywood Ave
Fairfield, NJ 07004
Tel: 1-800-522-4134
Email: Service@valeyappliancenj.com

This press release was submitted by Right Now Marketing Group, LLC

FreeEndlessTraffic.com Offers Targeted Traffic To Websites and Personal Blogs

0
0

(PRBuzz.com) April 16, 2013 -- John Tigart through his website through his website helps internet businesses and personal bloggers and claims his product "...to generate traffic to your website using simple yet effective techniques." For this purpose he came up with research and findings from the last 5 to 6 years of internet trends, online marketing issues and case studies and how to counter slow moving traffic counters.

Endless Free Traffic isn't a gadget or software that installs to the computer and starts engaging internet audience or drive traffic to website automatically. It is in fact a systematic module traffic generator carefully planned and implemented by the author himself to give effective and long lasting results. For an internet blogger or small scale business, online viewership means potential customers and capital generation. Using the right tool and techniques to help build up the traffic to websites is not rocket science, but with some helpful pointers and tips and insight on how to get the traffic going is beneficial in the long run. The author has come up with more than 20 modules out of which 5 are free bonuses for free targeted traffic. The modules come in handy, bounded pages that cover a range of topics with the except of the first module which is covered by 5 step by step videos on how to generate internet traffic, what methods to apply, a comparison with what big companies and small companies do differently when it comes to online marketing strategies, what traffic generators are most commonly used among others etc.

The remaining modules talk about the power of social media marketing, the sites and their statistics, how to link a blog to a Facebook page, Twitter handle, pinning items on Pinterest, etc. the growing trend of people shifting a major part of their social lives on the internet is why engaging the power of social media marketing is so important to get the masses to notice a personal blog or brand. Other modules talk about keyword search and search engine optimization to back link them to a certain site. The module teaches the basics and is a good starter even for people who consider themselves amateurs in the field. Bonuses include tips and tricks about list building, setting up blogs to make money and capitalizing space for advertisements by Google's pay-per-click. The entire set of modules is available in less than 10 US Dollars and can be shipped worldwide.

For more information, head over to http://www.freeendlesstraffic.com

Media Contact:

Free Endless Traffic
John Tigart
johntigart@yahoo.com
Houston, TX
http://www.freeendlesstraffic.com

Child Support Calculator Makes it Easy to Calculate Child Support for Divorced Parents

0
0

(PRBuzz.com) April 16, 2013 -- EChildSupportCalculator.com has been created to provide information about online calculator to help people get an approximate amount of child support payment by the non-custodial parent each month based on their inputs such as the person's income. The aim of the website is to help readers decide if Child Support Calculation is right for them or not. A family can go through different commotions and some of them have to be taken to court - divorce, determination of parenthood, alimony, annulment, etc. If there are children involved in all such cases, the judge's top priority will be the children's welfare.

Child Support is paid to the custodial parent, the guardian or the caregiver by the parent who doesn't have the custodial rights of the children. Generally the algorithm in all states is more or less the same for child support calculator. The child support amount is an estimation of expenses that includesthe basic necessities of a child, like food, clothing and healthcare (gifts are not counted). Each child is eligible to receive support from both parents, till the age of 18 years or until they are emancipated.

In some states the child support calculation has a certain additional elements that are included. For example, in Alabama the calculator includes the number of children that are subject of the support, the amount that is paid for child support from previous marriages, monthly alimony paid to a spouse from a previous marriage, costs per month for daycare paid by the custodial parent, the family health insurance paid by the custodial parent. Whereas, in Washington D.C. the calculation is much less complicated and includes the number of children that are included in the child support in question the age of the oldest child (it should be younger than 18 years), the gross annual income of the noncustodial parent and the annual expenses for the family health insurance; the gross annual income and the annual daycare costs are the figures taken into consideration from the custodial parent's side. The difference in elements makes it important that each state has a different child support calculator.

EChildSupportCalculator.com has updated information about child support calculators for different states such as Alabama, California, Colorado, Florida, Louisiana, Minnesota and Texas. There is plenty of information available on this website to enlighten people about Child Support Calculator and their modifications in different states.

For more information about Child Support Calculator please visit: http://echildsupportcalculator.com/

Media Contact:
Mitch Munoz
misyel8@gmail.com
Dallas, Texas
http://echildsupportcalculator.com/

Viewing all 3121 articles
Browse latest View live




Latest Images